📊 MHUAF Key Takeaways
Is Meihua International Medical Technologies Co., Ltd. (MHUAF) a Good Investment?
Meihua International Medical Technologies lacks publicly available SEC financial data necessary for fundamental analysis. With only 1 metric available and no recent filings, the company presents severe information asymmetry and transparency concerns. The absence of audited financial statements, cash flow data, and operational metrics makes informed investment impossible.
Meihua remained profitable through FY2024, with revenue of about $96.9 million, net income of about $10.8 million, strong gross margin near 34%, and a low-liability balance sheet. However, the latest SEC interim data for the six months ended June 30, 2025 shows weakening fundamentals: revenue fell about 16%, net income fell about 33%, operating cash flow turned negative at about $9.9 million outflow, and credit-loss expense more than doubled. The business still has balance-sheet capacity, but current growth quality and cash conversion have deteriorated enough to warrant a cautious view.
Meihua International Medical Technologies Co., Ltd. Key Strengths (MHUAF)
- Listed on OTC market indicating some level of public reporting
- Medical device sector offers growth potential if company demonstrates execution
- SIC classification in surgical instruments suggests focused industry segment
- Profitable in FY2024 with solid gross and operating margins for a medical consumables manufacturer
- Balance sheet remains lightly leveraged, with total liabilities far below equity and current assets well above current liabilities
- Equity base continued to grow into June 30, 2025, supported by retained earnings rather than heavy long-term debt
MHUAF Stock Risks: Meihua International Medical Technologies Co., Ltd. Investment Risks
- Critical data gap: No income statement, balance sheet, or cash flow information available
- No recent SEC filings or data freshness indicates potential non-compliance or dormant status
- Zero insider activity in last 90 days suggests lack of management confidence or engagement
- Impossible to assess profitability, solvency, liquidity, or operational efficiency
- OTC listing combined with data unavailability raises significant transparency red flags
- First-half 2025 showed declining sales and earnings, indicating weakening demand and lower operating momentum
- Cash conversion has deteriorated sharply, with negative operating cash flow driven by receivables build and working-capital pressure
- Large receivable exposure, including related-party balances and higher credit-loss provisioning, raises concerns about earnings quality
Key Metrics to Watch
- SEC EDGAR filing recency and completeness - verify current reporting status
- Revenue and profitability metrics once available - assess business model viability
- Balance sheet strength - evaluate financial stability and debt levels
- Operating cash flow - confirm business generates positive cash vs. accounting profits
- Management insider activity - gauge leadership confidence in company direction
- Accounts receivable and provision for credit losses versus revenue
- Operating cash flow and revenue trend in the next annual/interim SEC filing
Meihua International Medical Technologies Co., Ltd. (MHUAF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
MHUAF Profit Margin, ROE & Profitability Analysis
MHUAF vs Healthcare Sector: How Meihua International Medical Technologies Co., Ltd. Compares
How Meihua International Medical Technologies Co., Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Meihua International Medical Technologies Co., Ltd. Stock Overvalued? MHUAF Valuation Analysis 2026
Based on fundamental analysis, Meihua International Medical Technologies Co., Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Meihua International Medical Technologies Co., Ltd. Balance Sheet: MHUAF Debt, Cash & Liquidity
MHUAF Revenue Growth, EPS Growth & YoY Performance
MHUAF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Meihua International Medical Technologies Co., Ltd. (CIK: 0001835615)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Nov 14, 2024 | SC 13G | d865645dsc13g.htm | View → |
❓ Frequently Asked Questions about MHUAF
What is the AI rating for MHUAF?
Meihua International Medical Technologies Co., Ltd. (MHUAF) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MHUAF's key strengths?
Claude: Listed on OTC market indicating some level of public reporting. Medical device sector offers growth potential if company demonstrates execution. ChatGPT: Profitable in FY2024 with solid gross and operating margins for a medical consumables manufacturer. Balance sheet remains lightly leveraged, with total liabilities far below equity and current assets well above current liabilities.
What are the risks of investing in MHUAF?
Claude: Critical data gap: No income statement, balance sheet, or cash flow information available. No recent SEC filings or data freshness indicates potential non-compliance or dormant status. ChatGPT: First-half 2025 showed declining sales and earnings, indicating weakening demand and lower operating momentum. Cash conversion has deteriorated sharply, with negative operating cash flow driven by receivables build and working-capital pressure.
What is MHUAF's revenue and growth?
Meihua International Medical Technologies Co., Ltd. reported revenue of N/A.
Does MHUAF pay dividends?
Meihua International Medical Technologies Co., Ltd. does not currently pay dividends.
Where can I find MHUAF SEC filings?
Official SEC filings for Meihua International Medical Technologies Co., Ltd. (CIK: 0001835615) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MHUAF's EPS?
Meihua International Medical Technologies Co., Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MHUAF's fundamental grade?
Based on our AI fundamental analysis in June 2026, Meihua International Medical Technologies Co., Ltd. has a C grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MHUAF stock overvalued or undervalued?
Valuation metrics for MHUAF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MHUAF's AI grade for 2026?
Our dual AI analysis gives Meihua International Medical Technologies Co., Ltd. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MHUAF's free cash flow?
Meihua International Medical Technologies Co., Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does MHUAF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).